Program
mitapivat
Also written as “Mitapivat”, “AG-348” and “Mitapivat tablet”.
Its studies are mostly in beta-Thalassemia · Anemia, Hemolytic · Anemia, Sickle Cell · Anemia · Thalassemia, led by Agios Pharmaceuticals.
Drug pageMitapivat: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticals | 2410 open or running | phase 4since Mar 9, 2023 | Apr 2, 2014 | Mar 2029phase 3 · NCT07517133 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 7 earlier studies, Apr 2, 2014 to May 24, 2018.
- Dec 9, 2016Named mitapivatINNProposed as its International Nonproprietary Name in WHO's List 116 · before, AG-348
- Sep 10, 2018Phase 2 study in ThalassemiaNCT03692052 · 20 enrolled · United States, Canada, United Kingdom
- Feb 22, 2019Phase 3 study in Pyruvate Kinase Deficiency of Red CellsNCT03853798 · 90 enrolled · United States, Brazil, Canada and more
- Jul 13, 2020Phase 1 study in Healthy VolunteersNCT04472832 · 32 enrolled · United States
- Sep 22, 2020Phase 1 study in Healthy VolunteersNCT04565678 · 32 enrolled · United States
- Jan 4, 2021Phase 1 study in Healthy VolunteersNCT04696393 · 26 enrolled · United States
- Feb 18, 20212 phase 3 studiesNCT04770779, NCT04770753
- Jul 29, 2021Phase 3 study in Anemia, Sickle CellNCT05031780 · 286 enrolled · United States, Belgium, Brazil and more
- Nov 22, 20212 phase 3 studies in AnemiaNCT05175105, NCT05144256
- Nov 3, 2022Phase 1 study in Moderate Hepatic ImpairmentNCT05610657 · 20 enrolled · United States
- Mar 9, 2023Phase 4 study in Pyruvate Kinase Deficiency of Red CellsNCT05777993 · 55 planned · Belgium, Brazil, Canada and more
- Feb 23, 2024Phase 2 study in Anemia, Sickle CellNCT06286046
- Oct 17, 2024Phase 1 study in Healthy ParticipantsNCT06648824 · 20 enrolled · United States
- Mar 26, 20262 phase 3 studiesNCT07517133, NCT07506863
- Jun 15, 2026Phase 3 study in Anemia, Sickle CellNCT07656415 · 159 planned · United States
Ahead
- Mar 2029Primary completion: phase 3 study in Non-Transfusion-dependent Alpha-ThalassemiaNCT07517133
- Jun 2029Primary completion: phase 3 study in Transfusion-dependent Alpha-ThalassemiaNCT07506863
- Aug 2029Primary completion: phase 3 study in Anemia, Sickle CellNCT07656415
- Aug 2029Primary completion: phase 4 study in Pyruvate Kinase Deficiency of Red CellsNCT05777993
TargetBeta
“Pyruvate kinase isozymes R/L activator; Pyruvate kinase isozymes R/L activator; Pyruvate kinase isozymes R/L activator”ChEMBL 37, by rule
Other programs on PKLR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| etavopivat | Novo Nordisk | phase 3 | 12 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07656415Anemia, Sickle Cell · United States | 3 | Recruiting | Aug 2029 | 159 |
| NCT07517133Non-Transfusion-dependent Alpha-Thalassemia · United States | 3 | Recruiting | Mar 2029 | 45 |
| NCT07506863Transfusion-dependent Alpha-Thalassemia · United States | 3 | Recruiting | Jun 2029 | 54 |
| NCT06648824Healthy Participants · United States | 1 | Completed | Dec 3, 2024 | 20 |
| NCT06286046Anemia, Sickle Cell | 2 | Withdrawn | May 2027 | 0 |
| NCT05777993Pyruvate Kinase Deficiency of Red Cells · Belgium, Brazil, Canada and more | 4 | By invitation | Aug 2029 | 55 |
| NCT05610657Moderate Hepatic Impairment · United States | 1 | Completed | Jul 21, 2023 | 20 |
| NCT05175105Anemia · United States, Canada, France and more | 3 | Active, not recruiting | Dec 13, 2024 | 30 |
| NCT05144256Anemia · United States, Canada, Czechia and more | 3 | Active, not recruiting | May 3, 2024 | 49 |
| NCT05031780Anemia, Sickle Cell · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Oct 30, 2025 | 286 |
| NCT04770779Transfusion-dependent Alpha-Thalassemia · United States, Brazil, Bulgaria and more | 3 | Active, not recruiting | Apr 11, 2024 | 258 |
| NCT04770753Non-Transfusion-dependent Alpha-Thalassemia · United States, Brazil, Bulgaria and more | 3 | Active, not recruiting | Nov 13, 2023 | 194 |
| NCT04696393Healthy Volunteers · United States | 1 | Completed | Mar 19, 2021 | 26 |
| NCT04565678Healthy Volunteers · United States | 1 | Completed | Dec 3, 2020 | 32 |
| NCT04472832Healthy Volunteers · United States | 1 | Completed | Nov 23, 2020 | 32 |
| NCT03853798Pyruvate Kinase Deficiency of Red Cells · United States, Brazil, Canada and more | 3 | Completed | Jul 3, 2024 | 90 |
| NCT03692052Thalassemia · United States, Canada, United Kingdom | 2 | Active, not recruiting | Aug 20, 2020 | 20 |
| NCT03703505Healthy Volunteers · United States | 1 | Completed | Jun 1, 2018 | 8 |
| NCT03548220Pyruvate Kinase Deficiency of Red Cells · United States, Brazil, Canada and more | 3 | Completed | Oct 9, 2020 | 80 |
| NCT03559699Pyruvate Kinase Deficiency of Red Cells · United States, Canada, Denmark and more | 3 | Completed | Nov 12, 2020 | 27 |
| NCT03250598Healthy · United States | 1 | Completed | Oct 2, 2017 | 60 |
| NCT02476916Pyruvate Kinase Deficiency of Red Cells · United States, Canada, France and more | 2 | Completed | May 8, 2017 | 52 |
| NCT02149966Healthy Volunteer · United States | 1 | Completed | Nov 2014 | 48 |
| NCT02108106Healthy Volunteer · United States | 1 | Completed | Aug 2014 | 48 |
How it is read
Names in the registry
- “Mitapivat”, 13 entries
- “AG-348”, 10 entries
- “Mitapivat tablet”, 1 entry
- “Mitapivat 100 mg”, 1 entry
- “Mitapivat 300 mg”, 1 entry
Conditions, from the studies’ own filings
- beta-Thalassemia, 4 studies
- Anemia, Hemolytic, 4 studies
- Anemia, Sickle Cell, 3 studies
- Anemia, 2 studies
- Thalassemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.